Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases

Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases

The novel mRNA-based vaccines against SARS-CoV-2 display encouraging safety and efficacy profiles. However, there is a paucity of data regarding their immunogenicity and safety in patients with liver diseases (PWLD), especially in those with cirrhosis. We prospectively assessed anti-SARS-CoV-2 S-spi...

Full description

Bibliographic Details
Main Authors: Athanasios-Dimitrios Bakasis, Kleopatra Bitzogli, Dimitrios Mouziouras, Abraham Pouliakis, Maria Roumpoutsou, Andreas V. Goules, Theodoros Androutsakos
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Viruses
Subjects:
SARS-CoV-2
vaccination
liver diseases
cirrhosis
immunosuppression
Online Access:https://www.mdpi.com/1999-4915/14/2/207

Internet

https://www.mdpi.com/1999-4915/14/2/207

Similar Items